KRKG Stock Overview
Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Krka, d. d. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €125.00 |
| 52 Week High | €131.00 |
| 52 Week Low | €100.00 |
| Beta | 0.50 |
| 1 Month Change | -1.57% |
| 3 Month Change | 7.76% |
| 1 Year Change | 10.62% |
| 3 Year Change | 20.77% |
| 5 Year Change | 111.15% |
| Change since IPO | 1,476.00% |
Recent News & Updates
Are Investors Undervaluing Krka, d. d. (LJSE:KRKG) By 38%?
Jan 31
There's Reason For Concern Over Krka, d. d.'s (LJSE:KRKG) Price
Jan 09Recent updates
Are Investors Undervaluing Krka, d. d. (LJSE:KRKG) By 38%?
Jan 31There's Reason For Concern Over Krka, d. d.'s (LJSE:KRKG) Price
Jan 09Is Krka, d. d. (LJSE:KRKG) Trading At A 24% Discount?
Aug 05Krka d. d (LJSE:KRKG) Is Increasing Its Dividend To €6.60
Jul 14Does Krka d. d (LJSE:KRKG) Deserve A Spot On Your Watchlist?
May 24Krka d. d (LJSE:KRKG) Has Announced That It Will Be Increasing Its Dividend To €6.60
Apr 09Krka, d. d.'s (LJSE:KRKG) Intrinsic Value Is Potentially 25% Above Its Share Price
Jan 27Is There An Opportunity With Krka, d. d.'s (LJSE:KRKG) 48% Undervaluation?
Oct 26Here's Why We Think Krka d. d (LJSE:KRKG) Might Deserve Your Attention Today
Aug 30Krka d. d (LJSE:KRKG) Is Paying Out A Larger Dividend Than Last Year
Jun 24Is Now The Time To Put Krka d. d (LJSE:KRKG) On Your Watchlist?
May 19Krka d. d's (LJSE:KRKG) Upcoming Dividend Will Be Larger Than Last Year's
Apr 28If You Like EPS Growth Then Check Out Krka d. d (LJSE:KRKG) Before It's Too Late
Feb 14Are Investors Undervaluing Krka, d. d. (LJSE:KRKG) By 49%?
Nov 24Here's Why We Think Krka d. d (LJSE:KRKG) Is Well Worth Watching
Oct 30Are Investors Undervaluing Krka, d. d. (LJSE:KRKG) By 49%?
Aug 11Increases to Krka, d. d.'s (LJSE:KRKG) CEO Compensation Might Cool off for now
Jul 02Are Investors Undervaluing Krka, d. d. (LJSE:KRKG) By 43%?
Mar 30Is It Worth Buying Krka, d. d. (LJSE:KRKG) For Its 4.4% Dividend Yield?
Mar 11Krka, d. d.'s (LJSE:KRKG) Stock Has Fared Decently: Is the Market Following Strong Financials?
Feb 22What You Need To Know About Krka, d. d.'s (LJSE:KRKG) Investor Composition
Feb 03
Shareholders Of Krka d. d (LJSE:KRKG) Must Be Happy With Their 93% Return
Jan 14Calculating The Fair Value Of Krka, d. d. (LJSE:KRKG)
Dec 27Does Krka, d. d. (LJSE:KRKG) Have A Place In Your Dividend Portfolio?
Dec 09Could The Market Be Wrong About Krka, d. d. (LJSE:KRKG) Given Its Attractive Financial Prospects?
Nov 20Shareholder Returns
| KRKG | SI Pharmaceuticals | SI Market | |
|---|---|---|---|
| 7D | 0.8% | 3.2% | 0.1% |
| 1Y | 10.6% | 5.7% | 15.3% |
Return vs Industry: KRKG exceeded the SI Pharmaceuticals industry which returned 3.4% over the past year.
Return vs Market: KRKG underperformed the SI Market which returned 16.2% over the past year.
Price Volatility
| KRKG volatility | |
|---|---|
| KRKG Average Weekly Movement | 2.0% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 3.1% |
| 10% most volatile stocks in SI Market | 5.4% |
| 10% least volatile stocks in SI Market | 2.2% |
Stable Share Price: KRKG has not had significant price volatility in the past 3 months.
Volatility Over Time: KRKG's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1954 | 10,284 | Jože Colaric | www.krka.si |
Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. Its prescription pharmaceuticals include medicines for the treatment of cardiovascular, alimentary tract and metabolism, central nervous system, infections, oncology, and other diseases. The company also provides non-prescription products for oral cavity and pharynx; cough and cold; analgesics; nasal products; vitamin and mineral products; products for enhancing cerebral and peripheral circulation; products for enhancing digestive tract and digestion; health care products; and others.
Krka, d. d. Fundamentals Summary
| KRKG fundamental statistics | |
|---|---|
| Market cap | €3.85b |
| Earnings (TTM) | €313.95m |
| Revenue (TTM) | €1.81b |
12.3x
P/E Ratio2.1x
P/S RatioIs KRKG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KRKG income statement (TTM) | |
|---|---|
| Revenue | €1.81b |
| Cost of Revenue | €779.68m |
| Gross Profit | €1.03b |
| Other Expenses | €712.76m |
| Earnings | €313.95m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 16, 2024
| Earnings per share (EPS) | 10.18 |
| Gross Margin | 56.84% |
| Net Profit Margin | 17.38% |
| Debt/Equity Ratio | 0% |
How did KRKG perform over the long term?
See historical performance and comparison